Condition: Limited Stage Small Cell Lung Cancer · Sponsor: Shandong Cancer Hospital and Institute
This is a prospective, open,multicenter, randomized controlled phase III clinical trial. In patients with LS-SCLC who achieve remission after first-line chemoradiotherapy, the efficacy and safety of PCI or MRI surveillance is evaluated and analyzed. PCI is performed in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. MRI surveillance alone (delaying radiation until the actual brain metastasis) may be not inferior to PCI.
This description comes directly from the study's public registry record.
Jinming Yu, PhD · +8613806406293 · sdyujinming@126.com
Xiangjiao Meng, PhD · +8613793150996 · mengxiangjiao@126.com
Always discuss trial participation with your own doctor first.
| Shandong Cancer Hospital and Institute | Jinan, Shandong, China | Recruiting |
| Shandong Cancer Hospital | Jinan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04829708